Skip to main content

Advertisement

Log in

Essential thrombocytosis attributed to JAK2-T875N germline mutation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The aim of this study was to elucidate the role of a non-canonical JAK2 mutation JAK2-T875N, which was identified by exome sequencing in a patient with essential thrombocytosis (ET) who had a family history of suspecting ET. Whole exome sequencing was performed on peripheral blood mononuclear cells and buccal swab-derived genomic DNA. Sanger sequencing was performed to confirm the variant. We evaluated the function of the mutation on JAK2 activity and downstream signaling (Erk, STATs) using JAK2-T875N-transfected or transduced cell lines. 293T cells transfected with JAK2 cDNA carrying V617F or T875N mutations showed increased levels of phosphorylated JAK2 and Erk. Enhanced STAT3 and STAT5 activity was confirmed by promoter assay. JAK2-T875N-transduced Ba/F3 cells showed increased cellular growth without IL-3 stimulation. To our knowledge, this is the first case of ET caused by JAK2-T875N mutation with a family history of thrombocytosis and cerebral infarction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8. https://doi.org/10.1038/nature03546.

    Article  CAS  PubMed  Google Scholar 

  2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90. https://doi.org/10.1056/NEJMoa051113.

    Article  CAS  PubMed  Google Scholar 

  3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61. https://doi.org/10.1016/s0140-6736(05)71142-9.

    Article  CAS  PubMed  Google Scholar 

  4. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405. https://doi.org/10.1056/NEJMoa1312542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90. https://doi.org/10.1056/NEJMoa1311347.

    Article  CAS  PubMed  Google Scholar 

  6. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018. https://doi.org/10.1002/ajh.25303.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107(6):673–80. https://doi.org/10.1007/s12185-018-2421-7.

    Article  CAS  PubMed  Google Scholar 

  8. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998;18(1):49–52. https://doi.org/10.1038/ng0198-49.

    Article  CAS  PubMed  Google Scholar 

  9. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366(10):967–9. https://doi.org/10.1056/NEJMc1200349.

    Article  CAS  PubMed  Google Scholar 

  10. Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014;123(9):1372–83. https://doi.org/10.1182/blood-2013-05-504555.

    Article  CAS  PubMed  Google Scholar 

  11. Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, Seeliger MA, et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood. 2014;123(7):1059–68. https://doi.org/10.1182/blood-2012-12-473777.

    Article  CAS  PubMed  Google Scholar 

  12. Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009;114(15):3325–8. https://doi.org/10.1182/blood-2008-04-149047.

    Article  CAS  PubMed  Google Scholar 

  13. Scaife M, Pacienza N, Au BC, Wang JC, Devine S, Scheid E, et al. Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Ther. 2013;20(1):24–34. https://doi.org/10.1038/gt.2011.210.

    Article  CAS  PubMed  Google Scholar 

  14. Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, Sleep GT, et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA. 2004;101(48):16909–14. https://doi.org/10.1073/pnas.0407572101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yoshimitsu M, Higuchi K, Ramsubir S, Nonaka T, Rasaiah VI, Siatskas C, et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther. 2007;14(3):256–65. https://doi.org/10.1038/sj.gt.3302839.

    Article  CAS  PubMed  Google Scholar 

  16. Numata A, Shimoda K, Kamezaki K, Haro T, Kakumitsu H, Shide K, et al. Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway. J Biol Chem. 2005;280(13):12621–9. https://doi.org/10.1074/jbc.M408442200.

    Article  CAS  PubMed  Google Scholar 

  17. Mead AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, et al. Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood. 2013;121(20):4156–65. https://doi.org/10.1182/blood-2012-05-430926.

    Article  CAS  PubMed  Google Scholar 

  18. Zou H, Yan D, Mohi G. Differential biological activity of disease-associated JAK2 mutants. FEBS Lett. 2011;585(7):1007–13. https://doi.org/10.1016/j.febslet.2011.02.032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA. 2005;102(52):18962–7. https://doi.org/10.1073/pnas.0509714102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274–81. https://doi.org/10.1182/blood-2005-12-4824.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Frohling S, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood. 2006;108(8):2770–9. https://doi.org/10.1182/blood-2006-04-014712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. McWhinney CD, Dostal D, Baker K. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes. J Mol Cell Cardiol. 1998;30(4):751–61. https://doi.org/10.1006/jmcc.1998.0639.

    Article  CAS  PubMed  Google Scholar 

  23. Kirabo A, Kearns PN, Jarajapu YP, Sasser JM, Oh SP, Grant MB, et al. Vascular smooth muscle Jak2 mediates angiotensin II-induced hypertension via increased levels of reactive oxygen species. Cardiovasc Res. 2011;91(1):171–9. https://doi.org/10.1093/cvr/cvr059.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sun D, Moore S, Jakobs TC. Optic nerve astrocyte reactivity protects function in experimental glaucoma and other nerve injuries. J Exp Med. 2017;214(5):1411–30. https://doi.org/10.1084/jem.20160412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wong M, Li Y, Li S, Zhang S, Li W, Zhang P, et al. Therapeutic retrobulbar inhibition of STAT3 protects ischemic retina ganglion cells. Mol Neurobiol. 2015;52(3):1364–77. https://doi.org/10.1007/s12035-014-8945-9.

    Article  CAS  PubMed  Google Scholar 

  26. Wang DY, Ray A, Rodgers K, Ergorul C, Hyman BT, Huang W, et al. Global gene expression changes in rat retinal ganglion cells in experimental glaucoma. Investig Ophthalmol Vis Sci. 2010;51(8):4084–95. https://doi.org/10.1167/iovs.09-4864.

    Article  Google Scholar 

  27. Yang Z, Quigley HA, Pease ME, Yang Y, Qian J, Valenta D, et al. Changes in gene expression in experimental glaucoma and optic nerve transection: the equilibrium between protective and detrimental mechanisms. Investig Ophthalmol Vis Sci. 2007;48(12):5539–48. https://doi.org/10.1167/iovs.07-0542.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Professor Jeffrey A. Medin (Medical College of Wisconsin Milwaukee, WI, USA) for kindly providing lentiviral plasmids.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Makoto Yoshimitsu.

Ethics declarations

Conflict of interest

All authors declare that they have no competing financial interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshimitsu, M., Hachiman, M., Uchida, Y. et al. Essential thrombocytosis attributed to JAK2-T875N germline mutation. Int J Hematol 110, 584–590 (2019). https://doi.org/10.1007/s12185-019-02725-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02725-8

Keywords

Navigation